Syncona Limited Publication of Annual Report and Notice of AGM (6764D)
June 27 2019 - 6:44AM
UK Regulatory
TIDMSYNC
RNS Number : 6764D
Syncona Limited
27 June 2019
Syncona Limited
Publication of 2019 Annual Report and Notice of Annual General
Meeting
27 June 2019
Syncona Ltd, a leading healthcare company focused on founding,
building and funding global leaders in life science, today
announces that it has published its Annual Report and Accounts for
the year ended 31 March 2019 ("2019 Annual Report"). In addition,
Syncona has published its Notice of Annual General Meeting 2019 and
a circular relating to the 2019 Dividend.
In compliance with Listing Rule 9.6.1, these documents have
today been submitted to the National Storage Mechanism and will
shortly be available for inspection at
www.morningstar.co.uk/uk/nsm.
Copies of these documents, together with the Form of Proxy for
use in connection with the 2019 Annual General Meeting, Charitable
Allocation Form and Cash Election Form, are available
electronically on Syncona's website at
www.synconaltd.com/investors. Printed copies of these documents are
also being posted to shareholders where requested.
Syncona's Annual General Meeting will be held at 10:30am on 30
July 2019 at the offices of Citco Fund Services (Guernsey) Limited,
Arnold House, St Julian's Avenue, St Peter Port, Guernsey, GY1
3RD.
[ENDS]
Enquiries
Syncona Ltd
Siobhan Weaver / Annabel Clay
Tel : +44 (0) 20 3981 7940
FTI Consulting
Brett Pollard / Natalie Garland-Collins
Tel: +44 (0) 20 3727 1000
Copies of this press release and other corporate information can
be found on the company website at: www.synconaltd.com
About Syncona
Syncona is a leading FTSE250 healthcare company focused on
founding, building and funding global leaders in life science. Our
vision is to deliver transformational treatments to patients in
truly innovative areas of healthcare while generating superior
returns for shareholders.
We seek to partner with the best, brightest and most ambitious
minds in science to build globally competitive businesses.
We take a long-term view, underpinned by a deep pool of capital,
and are established leaders in gene and cell therapy. We focus on
delivering dramatic efficacy for patients in areas of high unmet
need.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ACSUBSRRKRANUAR
(END) Dow Jones Newswires
June 27, 2019 06:44 ET (10:44 GMT)
Syncona (LSE:SYNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syncona (LSE:SYNC)
Historical Stock Chart
From Apr 2023 to Apr 2024